Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. D.G. Knapen

Publicaties

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Independent transcriptional patterns reveal biological processes associated with disease-free survival in early colorectal cancer

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

Monoclonal antibody biosimilars for cancer treatment

Search for novel cancer treatments and reducing their side effects

Abstract 5611: LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy

Opportunities on the horizon for the management of early colon cancer

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment

89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice

Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)

Lees meer

Pers/media

Podcast over het coloncarcinoom